Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Boehringer Ingelheim. (6/2/14). "Press Release: New Data Show Giotrif (afatinib) Provided more than One Year Additional Survival for Lung Cancer Patients with the Most Common Type of EGFR Mutation (dell9) Compared to Chemotherapy [For Ex-US and Ex-UK Med

Organisations Organisation Boehringer Ingelheim (Group)
  Organisation 2 National Taiwan University
Products Product Giotrif®
  Product 2 clinical research
Person Person Malin, Reinhard (Boehringer Ingelheim 201505 Director Media + PR)
     


For Ex-US and Ex-UK Media Only


> Non-small cell lung cancer (NSCLC) patients with the del19 EGFR mutation lived a median of more than one year longer if they started treatment with afatinib rather than standard chemotherapy1

> Afatinib is the first treatment to demonstrate an overall survival benefit for patients with specific types of EGFR mutation-positive NSCLC1


Boehringer Ingelheim today announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6). These data, to be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), demonstrated for the first time that patients with NSCLC with the most common epidermal growth factor receptor (EGFR) mutation (exon 19 deletions; del19) lived more than one year longer if treated with first-line afatinib compared to chemotherapy.1

Del19 is the most common type of EGFR mutation. It accounts for 50% of all EGFR mutations. The prevalence of EGFR mutations is approximately 40% among Asian patients and 10-15% among Caucasian patients with lung adenocarcinoma.2,3,4 For patients with the del19 mutation afatinib prolonged survival by 12.2 months versus chemotherapy in the LUX-Lung 3 trial, and 13.0 months versus chemotherapy in the LUX-Lung 6 trial. 1

Principal investigator Professor James Chih-Hsin Yang, M.D., Ph.D., National Taiwan University Hospital in Taiwan commented: "NSCLC patients with the del19 EGFR mutation lived a median of more than one year longer if they started treatment with afatinib rather than standard chemotherapy. Afatinib is the first treatment to demonstrate an overall survival benefit for these patients.

LUX-Lung 3 and LUX-Lung 6 represent a potential change in the use of personalised medicine for treating patients with NSCLC. I think that these data support afatinib as the treatment of choice for patients with the del19 mutation."


Afatinib: approved and investigational indications

Afatinib (GIOTRIF® / GILOTRIF®) is indicated for the treatment of distinct types of EGFR mutation-positive NSCLC. Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF®. It is under regulatory review in other countries. Phase III trials in squamous head and neck cancer (HNSCC) and trials in other tumour types are ongoing.


About Afatinib:

http://www.newshome.com/oncology/lung-cancer/afatinib-backgrounder.aspx


About Boehringer Ingelheim in Oncology:

http://www.newshome.com/oncology/general-oncology/boehringer-ingelheim-oncology-research-and-development.aspx


Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.


References

1. Yang J, Sequist L et al. Overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring common (Del19/L858R) Epidermal Growth Factor Receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6] comparing afatinib with chemotherapy. Abstract #8004 presented at 2014 American Society of Clinical Oncology, 50th Annual Meeting, 30 May-3 June 2014, Chicago, IL, USA
2. Quest Diagnostics - Lung Cancer Mutation Panel; http://www.questdiagnostics.com/hcp/intguide/jsp/showintguidepage.jsp?fn=TS_LungCancerMutation_Panel.htm
3. Yang J et al. J Clin Oncol 2013;DOI: 10.1200/JCO.2012.46.1764
4. Wu Y-L et al. J Clin Oncol 2014;DOI:10.1016/S1470-2045(13)70604-1


Media contact

Boehringer Ingelheim
Media & PR
Dr Reinhard Malin
Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY
Phone + 49 - 6132 - 77 90815
Fax + 49 - 6132 - 77 6601

   
Record changed: 2017-04-02

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top